Benzinga | Dec 10, 2020 04:10PM EST

Sonoma Pharma Reports Exclusive Partnership With Crown Labs To Launch Microcyne Technology-Based Anti-Itch OTC Products

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing high performance stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, oral care, nasal care and dermatological conditions, and Crown Laboratories, Inc., a fully integrated global skin care company, announce they have entered into a license and supply agreement for the exclusive rights to sell and market products for the over-the-counter (OTC) dermatological market in the United States. Crown plans to sell Sonoma's Microcyn(r) technology dermal sprays and gels targeting itch and pain under Sarna(r), the #1 Dermatologist Recommended Anti-Itch Brand, with a unique variety of formulations to quickly relieve itch and skin irritations.

Sonoma's HOCl line of products are clinically proven to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. Sonoma will continue to sell its prescription strength products while Crown will distribute an OTC version available without prescription.

"Having access to Sonoma's Microcyn(r) technology provides us with the first in class hypochlorous acid-based products in the OTC dermatology market. We believe that integrating these new products into our portfolio of strong brands will provide greater patient access and help improve patient outcomes," said Jeff Bedard, Crown's CEO.

"Crown is committed to providing safe and effective solutions that relieve discomfort associated with compromised skin," said Steve Gallopo, Crown's Vice President, US/Global OTC Marketing. "Managing pruritus (itch) is essential as it is a major symptom associated with many skin ailments. We are thrilled to offer a clinically proven, steroid-free line of HOCl-products within the Sarna franchise as this represents a major advancement in combating itch within the OTC market."

"We are excited to partner with Crown Laboratories, which shares our passion of providing patients with access to highly effective health care products. In addition, Crown has extensive experience selling in OTC markets and this partnership will expand our OTC offerings to consumers across the United States and into online retail markets," said Amy Trombly, Sonoma's CEO.